Pulmovant

Pulmovant (operating at pulmovant.com) is a clinical-stage biotechnology company pioneering transformative therapies for pulmonary diseases. Founded in 2023, it operates under the Roivant umbrella (Nasdaq: ROIV), a biopharmaceutical services and development firm. Pulmovant’s mission is to redefine treatment paradigms for patients suffering from chronic respiratory conditions, beginning with its lead candidate, mosliciguat—a novel therapeutic targeting pulmonary hypertension and related disorders. Unlike conventional approaches that focus on symptom management, Pulmovant’s science-driven approach aims to address underlying disease mechanisms, offering a potential breakthrough for millions of affected individuals. By leveraging advanced biotech platforms, the company accelerates drug development while maintaining rigorous clinical standards. This positions Pulmovant as a critical player in the fight against debilitating pulmonary conditions, with implications for both patient outcomes and healthcare innovation.